æ¬æ¥
+0.57%
5æ¥é
-3.07%
1ã¶æ
-10.69%
6ã¶æ
-13.30%
å¹Žåæ¥
-7.05%
1幎é
-15.75%
⢠BNT113ãç¡å¢æªçåæéã®è©äŸ¡é ç®ãéæã§ããªãã£ãããšãåããããªã³ããã¯æ ªãäžèœã ⢠äºåèšå®ãããååŒèšç»ã«åºã¥ãçµå¶å¹¹éšã«ããæ ªåŒå£²åŽãæè¿å®æœãããã ⢠ããªã³ããã¯ã¯éæå£²äžé«33å3,000äžãã«ãšç޿倱ãå ±åã
⢠ããªã³ããã¯ãšãžã§ãã³ããã¯ã¯ãå€§è žããã察象ãšããããªãŒããžãŒã³ ã»ãã¡ã©ã³ãã®ç¬¬2çžèšåºè©ŠéšãçµäºããŸããã ⢠ç¬ç«ããŒã¿å®å šæ§ç£èŠå§å¡äŒã¯ãå詊éšã«èšåºçæå¹æ§ãæ¬ åŠããŠãããšçµè«ä»ããŸããã ⢠ããªã³ããã¯ã¯éæå£²äžé«33å3,000äžãã«ãçŽæå€±13å2,000äžãã«ãå ±åããŠããŸãã
⢠Povetaciceptã®æ²»éšãè çŸæ£ã«ãããäž»èŠè©äŸ¡é ç®ãéæã ⢠Vertexãè¿ é審æ»ã«åã3æãŸã§ã«BLAïŒçç©åŠçè£œå€æ¿èªç³è«ïŒãæåºããèšç»ã ⢠ã¢ããªã¹ããPovetaciceptã®åžå Žæœåšæ§ãšæ ªäŸ¡ã«å¯Ÿãè¯å®çãªèŠæ¹ã
⢠FDAã¯æå®³äºè±¡å ±åã«é¢ããéåã§èŠåæžãçºè¡ããã ⢠ã¢ããªã¹ãã¯ããã€ãã©ã€ã³ãç«¶åãžã®æžå¿µããããã»ãã«ãã£ã¹ã¯ã®æ Œä»ããåŒãäžããã ⢠å瀟ã®2026幎床ã¬ã€ãã³ã¹ã¯ãæžåæžçãäºæž¬ããŠããã


| æ ªäž»çµ±èš | æ¯ç |
|---|---|
| AT Impf GmbH | 40.05% |
| Medine GmbH | 15.87% |
| Fidelity Management & Research Company LLC | 2.15% |
| T. Rowe Price Investment Management, Inc. | 1.77% |
| çš®é¡ | æ¯ç |
|---|---|
| Corporation | 56.27% |
| Investment Advisor | 11.90% |
| Investment Advisor/Hedge Fund | 3.82% |
| Research Firm | 2.02% |
é¢é£éèåå